Abstract
Specific elimination of tumor cells by replication-competent viral vectors is mediated through active viral replication, spread in tumor tissue and direct cytopathic effects. In addition, immune responses are induced against virally infected tumor cells. Recently, oncolytic vectors were constructed with mutations in neurovirulence genes or DNA synthesis genes. Viral replication should only be restricted to malignant cells to prevent severe viral disease. These constructed vectors terminate cells by mechanisms different from standard anti-cancer therapies; they offer another treatment modality which can be used in combination with chemotherapy, radiotherapy and gene therapies with additive or synergistic effects. Combination therapies are usually necessary to control tumorigenic diseases. Inhibiting angiogenesis represents another new field in current anticancer treatment development. Combining an oncolytic virus with antiangiogenesis is able to potentiate both treatment effects compared to each treatment modality alone in both primary and advanced disease. This combination might be beneficial for cancer patients in the future. We have also outlined some relevant patents.
Keywords: Antiangiogenesis, cancer, combination therapy, oncolytic virus, patent, viral replication
Recent Patents on Anti-Cancer Drug Discovery
Title:Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Volume: 10 Issue: 2
Author(s): Matthias Karrasch and Christoph Rehfuess
Affiliation:
Keywords: Antiangiogenesis, cancer, combination therapy, oncolytic virus, patent, viral replication
Abstract: Specific elimination of tumor cells by replication-competent viral vectors is mediated through active viral replication, spread in tumor tissue and direct cytopathic effects. In addition, immune responses are induced against virally infected tumor cells. Recently, oncolytic vectors were constructed with mutations in neurovirulence genes or DNA synthesis genes. Viral replication should only be restricted to malignant cells to prevent severe viral disease. These constructed vectors terminate cells by mechanisms different from standard anti-cancer therapies; they offer another treatment modality which can be used in combination with chemotherapy, radiotherapy and gene therapies with additive or synergistic effects. Combination therapies are usually necessary to control tumorigenic diseases. Inhibiting angiogenesis represents another new field in current anticancer treatment development. Combining an oncolytic virus with antiangiogenesis is able to potentiate both treatment effects compared to each treatment modality alone in both primary and advanced disease. This combination might be beneficial for cancer patients in the future. We have also outlined some relevant patents.
Export Options
About this article
Cite this article as:
Karrasch Matthias and Rehfuess Christoph, Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (2) . https://dx.doi.org/10.2174/1574892810666150330152029
DOI https://dx.doi.org/10.2174/1574892810666150330152029 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
Current Drug Metabolism Bioprocessing of Baculovirus Vectors: A Review
Current Gene Therapy Serotonin and Cancer: What Is the Link?
Current Molecular Medicine The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets Organic Nanotheranostics for Photoacoustic Imaging-Guided Phototherapy
Current Medicinal Chemistry Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Nanotechnology and Radiopharmaceuticals: Diagnostic and Therapeutic Approaches
Current Drug Delivery In Silico Prediction and Validation of Oxygen-Regulated Protein N-myc Downstream Regulated Gene 3 and Virtual Screening of Competitive Inhibitors of L-Lactate as Therapeutics
Letters in Drug Design & Discovery Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates
Current Medicinal Chemistry Two Novel Heparin-binding Vascular Endothelial Growth Factor Splices, L-VEGF144 and L-VEGF138, are Expressed in Human Glioblastoma Cells
Current Neurovascular Research Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors
Current Drug Targets Advances in Gene Therapy for Bladder Cancer
Current Gene Therapy Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry